thisdrug what a medicine's name tells you

WHO naming stem · suffix · 44 listed names

-dipine

This page was written with AI.

calcium channel blockers, nifedipine derivatives

WHO's definition, quoted as written in the 2024 stem book

9 of 44 names appear in these lists: 9 in the US list (FDA Drugs@FDA) and 1 in the EU central list (EMA); 12 have national brands in at least one EU/EEA country.

Names only. This page is about -dipine as a part of a name. It has nothing on uses, doses, side effects or interactions of any medicine that carries it, and nothing here is medical advice. Ask a pharmacist or doctor about the medicine itself.

Where it sits in a name

WHO writes the stem as -dipine. So the letters dipine sit at the end of the name (…dipine).

All 44 names WHO lists under -dipine

These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.

Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 9 of 44 names appear in these lists: 9 in the US list (FDA Drugs@FDA) and 1 in the EU central list (EMA); 12 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.

  1. amlodipine
    US brands: KATERZIA, NORLIQVA, NORVASC, SDAMLO, AMVAZ (discontinued in FDA listings)
    in combination: AZOR with olmesartan; CADUET with atorvastatin; EXFORGE with valsartan; EXFORGE HCT with hydrochlorothiazide + valsartan; TRIBENZOR with hydrochlorothiazide + olmesartan; AMTURNIDE (discontinued in FDA listings) with aliskiren + hydrochlorothiazide; CONSENSI (discontinued in FDA listings) with celecoxib; LOTREL (discontinued in FDA listings) with benazepril; PRESTALIA (discontinued in FDA listings) with perindopril arginine; TEKAMLO (discontinued in FDA listings) with aliskiren; TWYNSTA (discontinued in FDA listings) with telmisartan; WIDAPLIK (discontinued in FDA listings) with indapamide + telmisartan
    EU (central) brands, in combination: Amlodipine / Valsartan Mylan with valsartan; Copalia with valsartan; Copalia HCT with hydrochlorothiazide + valsartan; Dafiro with valsartan; Dafiro HCT with hydrochlorothiazide + valsartan; Exforge with valsartan; Exforge HCT with hydrochlorothiazide + valsartan; Twynsta with telmisartan; Imprida (withdrawn) with valsartan; Imprida HCT (lapsed) with hydrochlorothiazide + valsartan; Onduarp (withdrawn) with telmisartan; Rasilamlo (withdrawn) with aliskiren; Rasitrio (withdrawn) with aliskiren + hydrochlorothiazide
  2. aranidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  3. azelnidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  4. barnidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  5. benidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  6. cilnidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  7. clevidipine
    US brands: CLEVIPREX
    EU (central) brands: none found
  8. cronidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  9. darodipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  10. dazodipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  11. dexniguldipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  12. efonidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  13. elgodipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  14. elnadipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  15. felodipine
    US brands: PLENDIL (discontinued in FDA listings)
    in combination: LEXXEL (discontinued in FDA listings) with enalapril
    EU (central) brands: none found
  16. flordipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  17. furnidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  18. iganidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  19. isradipine
    US brands: DYNACIRC (discontinued in FDA listings), DYNACIRC CR (discontinued in FDA listings)
    EU (central) brands: none found
  20. lacidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  21. lemildipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  22. lercanidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  23. levamlodipine
    US brands: CONJUPRI (discontinued in FDA listings)
    EU (central) brands: none found
  24. levniguldipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  25. manidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  26. mesudipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  27. nicardipine
    US brands: CARDENE, CARDENE SR (discontinued in FDA listings)
    EU (central) brands: none found
  28. nifedipine
    US brands: PROCARDIA XL, ADALAT (discontinued in FDA listings), ADALAT CC (discontinued in FDA listings), AFEDITAB CR (discontinued in FDA listings), PROCARDIA (discontinued in FDA listings)
    EU (central) brands: none found
  29. niguldipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  30. niludipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  31. nilvadipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  32. nimodipine
    US brands: NYMALIZE, NIMOTOP (discontinued in FDA listings)
    EU (central) brands: none found
  33. nisoldipine
    US brands: SULAR
    EU (central) brands: none found
  34. nitrendipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  35. olradipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  36. oxodipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  37. palonidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  38. pranidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  39. riodipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  40. sagandipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  41. sornidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  42. taludipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  43. teludipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  44. vatanidipine
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)

US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.

EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.

EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.

Names with these letters that are not calcium channel blockers, nifedipine derivatives

WHO lists these 2 names under -dipine, but says the stem is not used in its meaning here: group (b) of Part IV of the 2024 stem book, “INN in which the preferred stem has been used, but not in accordance with its definition”. The letters are marked where they sit; WHO’s note, where it gives one, is quoted as written. In these names, WHO’s definition of -dipine does not apply.

  1. budipineWHO’s note: central stimulant, antidepressant and antiparkinsonian
  2. prodipineWHO’s note: central stimulant antiparkinsonian

Decode another name

Decoded

oxodipine

Listed INNCarries 2 WHO stems, most specific first: -dipine …

  • -dipineend of the nameWHO lists it hereWHO definition: calcium channel blockers, nifedipine derivatives
  • -pin(e)end of the nameWHO definition: tricyclic compounds

“oxodipine” is an INN that WHO lists under -dipine in the 2024 stem book.

The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.

Source and licence

The definition of -dipine (Part II B) and the 44 names (Part IV, group (a)), and the 2 not in accordance with it (group (b)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .

Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.

Made with AI tools. · Privacy